Biogen, a pioneer in biotechnology, boasts the leading portfolio of medicines to treat multiple sclerosis and is pushing the boundary of research into novel therapies for patients living with serious neurological and autoimmune diseases. Fueled by world-class research and development, Biogen uses innovative science and cutting-edge technology to specialize in the discovery, development and delivery of therapies for patients with little to no treatment options. To this mission, Biogen is applying their expertise to solve some of the most complex neurological disorders, including: Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease, and amyotrophic lateral sclerosis. As Biogen helps uncover a deeper understanding of human biology, they will continue to pursue treatments for previously intractable diseases.
Business Website: https://www.biogen.com/
Year Founded: 1978
Number of Employees: 5,001-10,000